We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genomic Sequencing Augments Diagnosis of Lymphoid Cancer

By LabMedica International staff writers
Posted on 19 Feb 2018
Print article
Image: The HiSeq X whole genome sequencing system (Photo courtesy of Illumina).
Image: The HiSeq X whole genome sequencing system (Photo courtesy of Illumina).
Lymphoid cancers include diffuse large B-cell lymphomas (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). In recent years, several sequencing-based assays have been developed, but their clinical applicability and utility for patients with specific mutations still needs to be verified.

Next-generation sequencing technologies have been instrumental in accelerating discovery in cancer genomics via whole-genome sequencing (WGS), whole-transcriptome sequencing (RNA sequencing), and deep-targeted sequencing. Two methods are commonly used for such targeted approaches: capture hybridization–based sequencing and amplicon-based sequencing, each having its own advantages and disadvantages.

Scientists at the University of British Columbia (Vancouver, BC, Canada) and their colleagues established that hybrid-capture sequencing is the method of choice for sequencing “actionable” gene mutations across the most common forms of lymphoid cancer. Due to its applicability in routinely acquired formalin-fixed, paraffin-embedded tissues, this assay can be implemented by clinical laboratories into routine diagnostic workflows. A cohort of matched tumor and normal DNA specimens was assembled from 229 patients, including 30 CLL, 80 DLBCL, and 119 FL cases. Formalin-fixed paraffin-embedded (FFPE) tissue blocks and peripheral blood DNA samples for all FL and DLBCL cases were acquired from the BC Cancer Agency (Vancouver, BC, Canada) lymphoma tumor bank.

The team used various techniques to analyze the blood and tissue samples. These included for WGS, specimens for 66 of 229 patients from the original cohort were frozen and embedded in OCT compound for DNA and RNA extractions, as well as frozen sections for histological correlation; capture sequencing with the Illumina MiSeq; Amplicon and Sanger Sequencing; Whole-Genome Library Construction and Sequencing performed on an Illumina HiSeq2500 or HiSeqX instruments.

Samples were sequenced using a panel of 20 lymphoma-specific genes via capture hybridization using Sure Select and amplicon sequencing using Illumina TruSeq Custom Amplicon. The study focused on the development of a sequencing pipeline to personalize lymphoma management establishes feasibility of capture sequencing of routinely acquired FFPE tissue (DLBCL) and fresh cell preparations (CLL) in a single assay. The team demonstrated the superiority of hybrid-capture sequencing over amplicon-based method with respect to assay sensitivity in an approach intended to cover a large capture space across the coding region of 32 genes.

Christian Steidl, MD, an Associate Professor and senior investigator of the study, said, “Our developed assay harnesses the power of modern sequencing for clinical diagnostics purposes and potentially better deployment of novel treatments in lymphoid cancers. We believe our study will help establish evidence-based approaches to decision making in lymphoid cancer care.” The study was published on February 8, 2018, in The Journal of Molecular Diagnostics.

Related Links:
University of British Columbia
BC Cancer Agency

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.